Blood Compatibility of Drug-Inorganic Hybrid in Human Blood: Red Blood Cell Hitchhiking and Soft Protein Corona.
biocompatibility
blood compatibility
drug-delivery system
hitchhiking
human plasma
layered double hydroxide
methotrexate
protein corona
red blood cell
Journal
Materials (Basel, Switzerland)
ISSN: 1996-1944
Titre abrégé: Materials (Basel)
Pays: Switzerland
ID NLM: 101555929
Informations de publication
Date de publication:
30 Sep 2023
30 Sep 2023
Historique:
received:
10
08
2023
revised:
16
09
2023
accepted:
27
09
2023
medline:
14
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
A drug-delivery system consisting of an inorganic host-layered double hydroxide (LDH)-and an anticancer drug-methotrexate (MTX)-was prepared via the intercalation route (MTX-LDH), and its hematocompatibility was investigated. Hemolysis, a red blood cell counting assay, and optical microscopy revealed that the MTX-LDH had no harmful toxic effect on blood cells. Both scanning electron microscopy and atomic force microscopy exhibited that the MTX-LDH particles softly landed on the concave part inred blood cells without serious morphological changes of the cells. The time-dependent change in the surface charge and hydrodynamic radius of MTX-LDH in the plasma condition demonstrated that the proteins can be gently adsorbed on the MTX-LDH particles, possibly through protein corona, giving rise to good colloidal stability. The fluorescence quenching assay was carried out to monitor the interaction between MTX-LDH and plasma protein, and the result showed that the MTX-LDH had less dynamic interaction with protein compared with MTX alone, due to the capsule moiety of the LDH host. It was verified by a quartz crystal microbalance assay that the surface interaction between MTX-LDH and protein was reversible and reproducible, and the type of protein corona was a soft one, having flexibility toward the biological environment.
Identifiants
pubmed: 37834660
pii: ma16196523
doi: 10.3390/ma16196523
pmc: PMC10573551
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Science and ICT (MSIT, Korea) & Korean National Police Agency
ID : RS-2023-00236429
Organisme : Korea Water Cluster (KWC)
ID : Korea Water Cluster ProjectLab
Références
J Parasitol. 1947 Aug;33(4):345-50
pubmed: 20256984
Biomaterials. 2004 Jul;25(15):3059-64
pubmed: 14967539
Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):275-81
pubmed: 19775871
Acta Biomater. 2015 Jan;11:68-79
pubmed: 25234158
Annu Rev Biomed Eng. 2021 Jul 13;23:225-248
pubmed: 33788581
Luminescence. 2017 Aug;32(5):873-879
pubmed: 28071855
Chem Commun (Camb). 2014 Nov 25;50(91):14071-81
pubmed: 24955443
Sci Rep. 2019 Mar 26;9(1):5147
pubmed: 30914741
Pharmaceutics. 2022 Nov 26;14(12):
pubmed: 36559099
Sci Adv. 2019 Nov 13;5(11):eaax9250
pubmed: 31763454
Colloids Surf B Biointerfaces. 2016 Sep 1;145:87-94
pubmed: 27137807
Chem Asian J. 2009 Jan 5;4(1):67-73
pubmed: 18988236
Nanomedicine (Lond). 2017 Sep;12(17):2113-2135
pubmed: 28805542
Mater Sci Eng C Mater Biol Appl. 2014 Jun 1;39:56-60
pubmed: 24863197
Nat Commun. 2018 Jul 11;9(1):2684
pubmed: 29992966
Adv Drug Deliv Rev. 2009 Jun 21;61(6):428-37
pubmed: 19376175
Langmuir. 2012 Jun 5;28(22):8433-45
pubmed: 22551342
Small. 2019 Aug;15(34):e1902333
pubmed: 31250985
J Biomater Sci Polym Ed. 1991;2(3):183-202
pubmed: 1854684
Br J Haematol. 1983 Aug;54(4):543-52
pubmed: 6871106
Chem Res Toxicol. 2018 Oct 15;31(10):1061-1068
pubmed: 30207453
ACS Nano. 2012 Aug 28;6(8):6730-40
pubmed: 22804333
Mater Sci Eng C Mater Biol Appl. 2013 May 1;33(4):2168-74
pubmed: 23498245
RSC Adv. 2018 Dec 5;8(71):40611-40620
pubmed: 35557920
ACS Nano. 2011 Feb 22;5(2):1366-75
pubmed: 21294526
ACS Appl Mater Interfaces. 2017 Oct 4;9(39):34185-34193
pubmed: 28915005
Biomacromolecules. 2017 Jun 12;18(6):1762-1771
pubmed: 28511014
ACS Nano. 2011 May 24;5(5):3693-700
pubmed: 21500856
Int J Mol Sci. 2022 Sep 26;23(19):
pubmed: 36232669
Eur J Pharm Biopharm. 2009 Oct;73(2):285-91
pubmed: 19539757
Drug Deliv Transl Res. 2017 Apr;7(2):259-275
pubmed: 28050892
Stroke. 2001 Apr;32(4):1005-11
pubmed: 11283404
Biomaterials. 2015 Nov;68:77-88
pubmed: 26276693
Anal Biochem. 1981 Jul 1;114(2):199-227
pubmed: 7030122
Drug Deliv Transl Res. 2022 Nov;12(11):2634-2648
pubmed: 35499717
Drug Deliv Transl Res. 2021 Jun;11(3):1096-1106
pubmed: 32779111
J Nanosci Nanotechnol. 2007 Nov;7(11):3700-5
pubmed: 18047040
Biomaterials. 2014 Mar;35(10):3331-9
pubmed: 24456604
Leukemia. 1993 Jul;7(7):1000-4
pubmed: 7686600
Arch Biochem Biophys. 2019 Oct 30;675:108118
pubmed: 31574256
Colloids Surf B Biointerfaces. 2014 Nov 1;123:143-9
pubmed: 25262409
Biomaterials. 2017 Dec;149:12-28
pubmed: 28988061
Colloids Surf B Biointerfaces. 2018 Jun 1;166:330-338
pubmed: 29609156
Mol Pharm. 2008 Jul-Aug;5(4):487-95
pubmed: 18510338
J Hazard Mater. 2021 Jul 15;414:125582
pubmed: 34030421
Mol Pharm. 2010 Dec 6;7(6):2141-7
pubmed: 20831257
Nat Rev Mater. 2023 Mar 24;:1-17
pubmed: 37361608
Adv Mater. 2019 Nov;31(45):e1805740
pubmed: 30589115
ACS Nano. 2013 Nov 26;7(11):10066-74
pubmed: 24128271
Pharm Res. 2011 Aug;28(8):1819-30
pubmed: 21213021
Environ Sci Pollut Res Int. 2017 Sep;24(27):21671-21679
pubmed: 28755146
Pharm Res. 2010 May;27(5):735-8
pubmed: 20198409
Front Pharmacol. 2021 Feb 19;12:618411
pubmed: 33679401
Pharmaceutics. 2020 Dec 14;12(12):
pubmed: 33327415
Int J Lab Hematol. 2013 Jun;35(3):351-7
pubmed: 23480230
J Mater Chem B. 2016 Mar 21;4(11):2008-2016
pubmed: 32263078
Spectrochim Acta A Mol Biomol Spectrosc. 2015;151:40-7
pubmed: 26123604
Acc Chem Res. 2017 Jun 20;50(6):1383-1390
pubmed: 28480714
Int J Biol Macromol. 2022 Mar 15;201:193-202
pubmed: 35007629
ACS Nano. 2010 Jan 26;4(1):365-79
pubmed: 20020753
J Fluoresc. 2017 Mar;27(2):619-628
pubmed: 27924439
Adv Drug Deliv Rev. 2022 Sep;188:114459
pubmed: 35850372
Adv Enzyme Regul. 1980;18:349-71
pubmed: 7446303
ACS Appl Mater Interfaces. 2014 Sep 10;6(17):15412-9
pubmed: 25144382
Eur J Pharm Sci. 2008 Dec 18;35(5):371-82
pubmed: 18762252
Eur J Med Chem. 2018 Oct 5;158:502-516
pubmed: 30243154